Stockreport

Exelixis: The Double Backbone Potential Of CABOMETYX And Zanzalintinib [Seeking Alpha]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF CABOMETYX remains a durable cash generator, while zanzalintinib is expected to drive significant growth, with peak sales estimates of $5B by 2033. 2026 guidance proje [Read more]